GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Eli Lilly and Co (CHIX:LLYz) » Definitions » Cyclically Adjusted Price-to-FCF

Eli Lilly and Co (CHIX:LLYZ) Cyclically Adjusted Price-to-FCF : 231.25 (As of Jan. 09, 2025)


View and export this data going back to 2013. Start your Free Trial

What is Eli Lilly and Co Cyclically Adjusted Price-to-FCF?

As of today (2025-01-09), Eli Lilly and Co's current share price is CHF740.00. Eli Lilly and Co's Cyclically Adjusted FCF per Share for the quarter that ended in Sep. 2024 was CHF3.20. Eli Lilly and Co's Cyclically Adjusted Price-to-FCF for today is 231.25.

The historical rank and industry rank for Eli Lilly and Co's Cyclically Adjusted Price-to-FCF or its related term are showing as below:

CHIX:LLYz' s Cyclically Adjusted Price-to-FCF Range Over the Past 10 Years
Min: 16.39   Med: 34.43   Max: 279.06
Current: 236

During the past years, Eli Lilly and Co's highest Cyclically Adjusted Price-to-FCF was 279.06. The lowest was 16.39. And the median was 34.43.

CHIX:LLYz's Cyclically Adjusted Price-to-FCF is ranked worse than
93.56% of 295 companies
in the Drug Manufacturers industry
Industry Median: 29.45 vs CHIX:LLYz: 236.00

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.

Eli Lilly and Co's adjusted free cash flow per share data for the three months ended in Sep. 2024 was CHF-0.430. Add all the adjusted free cash flow per share for the past 10 years together and divide 10 will get our Cyclically Adjusted FCF per Share, which is CHF3.20 for the trailing ten years ended in Sep. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Eli Lilly and Co Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for Eli Lilly and Co's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Eli Lilly and Co Cyclically Adjusted Price-to-FCF Chart

Eli Lilly and Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only 34.22 44.71 68.58 84.88 164.46

Eli Lilly and Co Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 137.06 164.46 215.53 255.76 265.60

Competitive Comparison of Eli Lilly and Co's Cyclically Adjusted Price-to-FCF

For the Drug Manufacturers - General subindustry, Eli Lilly and Co's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Eli Lilly and Co's Cyclically Adjusted Price-to-FCF Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Eli Lilly and Co's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Eli Lilly and Co's Cyclically Adjusted Price-to-FCF falls into.



Eli Lilly and Co Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

Eli Lilly and Co's Cyclically Adjusted Price-to-FCF for today is calculated as

Cyclically Adjusted Price-to-FCF=Share Price/ Cyclically Adjusted FCF per Share
=740.00/3.2
=231.25

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Eli Lilly and Co's Cyclically Adjusted FCF per Share for the quarter that ended in Sep. 2024 is calculated as:

For example, Eli Lilly and Co's adjusted Free Cash Flow per Share data for the three months ended in Sep. 2024 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Sep. 2024 (Change)*Current CPI (Sep. 2024)
=-0.43/133.0289*133.0289
=-0.430

Current CPI (Sep. 2024) = 133.0289.

Eli Lilly and Co Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201412 0.614 99.070 0.824
201503 -0.435 99.621 -0.581
201506 0.515 100.684 0.680
201509 0.713 100.392 0.945
201512 0.413 99.792 0.551
201603 -0.345 100.470 -0.457
201606 1.058 101.688 1.384
201609 1.316 101.861 1.719
201612 1.477 101.863 1.929
201703 -0.627 102.862 -0.811
201706 1.309 103.349 1.685
201709 1.306 104.136 1.668
201712 1.182 104.011 1.512
201803 0.181 105.290 0.229
201806 -0.327 106.317 -0.409
201809 1.719 106.507 2.147
201812 0.801 105.998 1.005
201903 -0.091 107.251 -0.113
201906 0.819 108.070 1.008
201909 1.261 108.329 1.549
201912 1.757 108.420 2.156
202003 0.117 108.902 0.143
202006 2.060 108.767 2.520
202009 1.397 109.815 1.692
202012 0.967 109.897 1.171
202103 1.228 111.754 1.462
202106 1.241 114.631 1.440
202109 1.191 115.734 1.369
202112 1.753 117.630 1.982
202203 1.684 121.301 1.847
202206 0.397 125.017 0.422
202209 1.685 125.227 1.790
202212 1.054 125.222 1.120
202303 0.847 127.348 0.885
202306 -0.204 128.729 -0.211
202309 -1.811 129.860 -1.855
202312 -1.878 129.419 -1.930
202403 0.082 131.776 0.083
202406 0.063 132.554 0.063
202409 -0.430 133.029 -0.430

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Eli Lilly and Co  (CHIX:LLYz) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


Eli Lilly and Co Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of Eli Lilly and Co's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Eli Lilly and Co Business Description

Industry
Address
Lilly Corporate Center, Indianapolis, IN, USA, 46285
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.

Eli Lilly and Co Headlines

No Headlines